Author Archives: Forest Ray PhD

#CureSMA2021 – Spinraza Leads to Better Swallowing, Farther Walking

Children with spinal muscular atrophy (SMA) who started taking Spinraza (nusinsersen) before symptoms appeared retained their ability to swallow after approximately four years, while youngsters with later-onset SMA walked farther with less fatigue. These results, from analyses performed on multiple ongoing clinical trials, were presented by Biogen,…

#CureSMA2021 – Evrysdi Shows Promise as Secondary Therapy

Editor’s note: The SMA News Today team is providing in-depth coverage of the 2021 Virtual SMA Research & Clinical Care Meeting, held June 9–11. Go here to read stories from the conference.  Evrysdi (risdiplam) appeared both safe and effective when used after other therapies to treat five…

Health Canada Approves Evrysdi for At-home Treatment

Evrysdi (risdiplam) has been approved by Health Canada for the at-home treatment of spinal muscular atrophy (SMA) in people ages 2 months and older. “The Health Canada approval of Evrysdi is a welcome addition in our ability to treat SMA. It is an efficacious treatment that significantly increases…

Scholar Rock Wins US Patent for Apitegromab

The United States Patent and Trademark Office has granted Scholar Rock a patent for apitegromab, with add-on and combination therapies, for treating muscle conditions such as spinal muscular atrophy (SMA). “We are delighted to have been granted this unique patent that further protects our myostatin approach to…